GlassScriptPhysician profile
Jason Wayne Wilson
NPI 1811159452
$538,455.89
in general payments reported to CMS, 2019-2025
22 companies · $29K in 2025
The $29K reported for 2025 was more than what 99% of Emergency Medicine providers received nationally (typical 2025 total: $57.10).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $84K · 2020: $48K · 2021: $94K · 2022: $134K · 2023: $79K · 2024: $71K · 2025: $29K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $90K · Consulting Fee: $65K · Travel and Lodging: $20K · Food and Beverage: $3,631 · Gift: $147 · Education: $9.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $89,890.00 |
| Consulting Fee | $65,447.00 |
| Travel and Lodging | $19,963.81 |
| Food and Beverage | $3,631.34 |
| Gift | $147.17 |
| Education | $9.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $175,474.35 | 2019-2024 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $103,151.95 | 2022-2024 | Andexxa |
| Gilead Sciences, INC. | $80,616.38 | 2019-2025 | Veklury |
| Portola Pharmaceuticals, LLC | $37,504.76 | 2019-2020 | |
| Alexion Pharmaceuticals, INC. | $34,677.68 | 2021-2022 | |
| Pfizer INC. | $22,671.08 | 2019-2023 | |
| Paratek Pharmaceuticals, INC. | $22,266.31 | 2021-2023 | Nuzyra |
| Acelrx Pharmaceuticals, INC. | $16,860.96 | 2020-2021 | |
| Abbott Laboratories | $15,694.10 | 2021-2025 | I-Stat |
| Biomerieux INC | $11,176.86 | 2024 | |
| Indivior INC. | $6,591.89 | 2025 | |
| Eagle Pharmaceuticals, INC. | $4,280.87 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $3,595.66 | 2019 | |
| Cepheid | $3,500.00 | 2022 | |
| Memed US, INC. | $147.17 | 2025 | Memed Bv |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Heartflow, INC. | $115.90 | 2024 | |
| Ethicon US, LLC | $34.16 | 2025 | Enseal |
| Lilly USA, LLC | $33.21 | 2019 | |
| Pear Therapeutics (US), INC. | $28.29 | 2021 | |
| Abbvie INC. | $20.71 | 2023 | |
| Novartis Pharmaceuticals Corporation | $13.60 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jason Wilson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.